SA
SMMT logo
Summit Therapeutics Inc.(SMMT)
Closing price · checked 4:46 PM ETAbout this dataData status
$10.56▲0.06 (0.57%)
After Hours:$10.50-0.06 (-0.57%)· 4:46 PM ET

S&P 500, Nasdaq, Russell 2000 below the 200-day average · VIX 28.4 · elevated volatility

Overview →

Summit Therapeutics Inc. (SMMT)

R&D to Revenue

0.00%

Fiscal year · Period ending:

SMMT logo

SMMT R&D to Revenue

Latest reported0.00%
SMMT FY R&D/Revenue (2549.34% → 0.00%)
High-resolution chart · PNG

What is r&d to revenue?

R&D spending as percentage of revenue.

SMMT r&d to revenue history

Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.

Summit Therapeutics Inc. R&D to Revenue — Annual fiscal periods
Period endingR&D to Revenue
0%
0%
0%
7,375.7447%
4,718.1868%
6,194.6512%
5,357.8786%
85.9533%
204.5384%
797.6431%
1,315.847%
551.7479%
358.5141%
249.657%
275.9873%
303.4077%
1,218.1026%
2,767.0371%
254.5228%
285.503%
193.271%
237.1689%
2,549.3421%

Frequently asked questions: SMMT r&d to revenue

What is Summit Therapeutics Inc. (SMMT)'s current r&d to revenue?

Summit Therapeutics Inc. (SMMT)'s latest reported r&d to revenue (Fiscal year) is 0.00% as of Dec 31, 2025. R&D spending as percentage of revenue.

How much historical r&d to revenue data is available for SMMT?

Stock Alarm Pro provides 23 dated annual fiscal periods observations for Summit Therapeutics Inc. (SMMT)'s r&d to revenue, allowing investors to analyze multi-year trends and cycle inflection points in Chart Studio.

How can I compare SMMT's r&d to revenue to peers or set an alert?

You can open SMMT's r&d to revenue in Stock Alarm Pro Chart Studio to overlay price and valuation multiples, or set real-time alerts on SMMT delivered by push, email, or phone call.

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.